Literature DB >> 2984636

Long-term protective immunity of recipients of the OKA strain of live varicella vaccine.

Y Asano, T Nagai, T Miyata, T Yazaki, S Ito, K Yamanishi, M Takahashi.   

Abstract

In spite of close contacts with patients who had varicella, 101 of 106 (95%) healthy and sick children (142 of 147 (97%) exposures of these children) who had received the OKA strain of live varicella vaccine 7 to 10 years earlier were protected against the disease completely. Among them, 37 of 38 (97%) vaccine recipients who received immunologic testing had varicella-zoster virus (VZV) antibodies tested by fluorescent antibody to membrane antigen method with a geometric mean titer of 1:9.3, and 37 of the 38 (97%) showed positive skin reaction to varicella-zoster virus antigen with erythema (mean diameter 13.4 mm). These findings were compared with those for 29 children who had contracted typical varicella 7 to 10 years earlier, whose seropositive rate was 100% with a geometric mean titer of 1:10.5, and 97% of whom (28/29) had positive skin reaction with mean diameter of 12.9 mm. These results indicate that the vaccine-induced protective immunity persists for approximately one decade and is almost equal to the long-term immunity following natural infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984636

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  21 in total

Review 1.  Varicella vaccination--a critical review of the evidence.

Authors:  S A Skull; E E Wang
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

2.  Varicella control and vaccine coverage: issues and challenges.

Authors:  Tamara Wallington; Erica Weir
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

Review 3.  25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview.

Authors:  M Takahashi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

5.  Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children.

Authors:  A Y Tan; C J Connett; G J Connett; S C Quek; H K Yap; F Meurice; B W Lee
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

6.  Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group.

Authors:  N J Webb; M M Fitzpatrick; D A Hughes; T J Brocklebank; B A Judd; M A Lewis; R J Postlethwaite; P A Smith; G Corbitt
Journal:  Arch Dis Child       Date:  2000-02       Impact factor: 3.791

7.  Risk factors for breakthrough varicella in healthy children.

Authors:  Y J Lim; F T Chew; A Y Tan; B W Lee
Journal:  Arch Dis Child       Date:  1998-12       Impact factor: 3.791

8.  Immunisation against chickenpox.

Authors:  L F Ross; J D Lantos
Journal:  BMJ       Date:  1995-01-07

9.  Prophylaxis or modification of varicella by oral acyclovir after household exposure.

Authors:  Y Asano; S Suga; T Yoshikawa; T Ozaki
Journal:  Arch Dis Child       Date:  1994-05       Impact factor: 3.791

10.  Three-year follow-up of protection rates in children given varicella vaccine.

Authors:  David W Scheifele; Scott A Halperin; Francisco Diaz-Mitoma
Journal:  Can J Infect Dis       Date:  2002-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.